Filing Flows › Vivos Therapeutics (VVOS) › Q2 2026
Vivos Therapeutics (VVOS) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 14, 2026
Vivos Therapeutics (VVOS) reported revenue of $5.2M for the second quarter 2026 (Q2 2026), +35% from a year earlier and +0.2% from the quarter before. Operating margin was -93.6%, net loss $5.5M (107.2% of revenue).
Vivos Therapeutics, Q2 2026: revenue $5.2M (+35% year over year), operating margin -93.6%, net loss $5.5M, operating cash flow −$3.1M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $5.2M | +0.2% | +35% |
| Operating profit | −$4.8M | — | — |
| Net earnings | −$5.5M | — | — |
| Operating cash flow | −$3.1M | — | — |
What changed
Revenue was $5.2M in Q2 2026, up 35% year over year and roughly flat from the previous quarter. Sleep Testing Services was the largest line at 46% of revenue. Sleep Testing Services added $1.5M year over year (up 183%), 116% of the total change. VIP declined 91%.
Gross margin was 57.3%, up 2.1 points from Q2 2025. Operating costs exceeded revenue by $4.8M, an operating margin of -93.6%. Operating expenses grew 12% against revenue growth of 35%. The fastest-growing cost line was Other operating costs (+67%). The quarter ended with a net loss of $5.5M, narrower than the previous quarter's $7.8M loss. Minority interests bore $42K of it: to shareholders the quarter was a loss of $5.5M.
Operating cash flow was −$3.1M. Non-cash charges added back $510K of depreciation and amortization and $50K of share-based compensation. Working capital and other items added $1.8M. Capital expenditures of $416K exceeded it, leaving free cash flow of −$3.6M.
Questions
What was Vivos Therapeutics' revenue in the second quarter 2026?
Vivos Therapeutics (VVOS) reported revenue of $5.2M for the second quarter 2026 (Q2 2026), +35% from a year earlier and +0.2% from the quarter before.
Was Vivos Therapeutics profitable in the second quarter 2026?
Operating loss was $4.8M (-93.6% of revenue) and net loss $5.5M.
Source: Vivos Therapeutics 10-Q on SEC EDGAR.